Erratum. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen Diabetes Care 2025;48:1607-1611.
Eldor. Roy R; Avraham. Noa N; Rosenberg. Orit O; Shpigelman. Miriam M; Golan-Cohen. Avivit A; Cukierman-Yaffe. Tali T; Merzon. Eugene E; Buch. Assaf A
Key Findings
- No new efficacy or safety data were presented
- The only change is the correct affiliation for author Assaf Buch
Practical Outcomes
- There’s nothing to apply to dosing or protocols – the notice only corrects a clerical error.
Summary
The paper is just an erratum fixing the listed affiliation of one author; it doesn’t contain any new study results or guidance on using semaglutide.
Abstract
In the article cited above, the affiliations for author Assaf Buch were incorrectly given as Diabetes Unit, Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, and Department of Nutritional Sciences, School of Health Sciences, Ariel University, Ariel, Israel. The sole affiliation for this author is Department of Nutritional Sciences, School of Health Sciences, Ariel University, Ariel, Israel. The online version of the article (https://doi.org/10.2337/dc25-0690) has been updated with the correct affiliation information.
Study Information
pubmed
2025
2025-12-03T00:00:00.000Z
10.2337/dc26-er02a